PTC Therapeutics, Inc.

Robbins Arroyo LLP Is Investigating the Officers and Directors of PTC Therapeutics, Inc. (PTCT) on Behalf of Shareholders

Robbins Arroyo LLP is investigating whether certain officers and directors of PTC Therapeutics, Inc. (NASDAQGS: PTCT) violated federal securities laws by issuing materially misleading business information to the investing public. PTC Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes.

PTC Therapeutics Discloses Its New Drug Application Was Not Approved

On February 23, 2016, PTC Therapeutics stock fell by over 60% after the company announced that it had received a Refuse to File letter from the U.S. Food and Drug Administration (“FDA”) regarding its New Drug Application for its lead drug candidate, Translarna. The FDA contended that the application was not complete enough to allow it to perform a substantive review of the drug. PTC shares have further declined since the announcement, closing at only $7.99 per share on February 26, 2016.

PTC Therapeutics Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, or you can complete the form below and we will contact you directly.

 

Shareholder Information

Items marked with an asterisk (*) are required information.

First Name * Last Name *
Phone *
E-mail * Confirm: E-mail *
Number of Shares Owned:
Comments:

Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

* I have read the disclaimer information
+=

    Send This Post

    Tags: